# Heng Zhu

Heng Zhu is a molecular biologist and proteomics technologist at the Johns Hopkins University School of Medicine, educated in China and known for co-inventing functional protein microarrays, laboratory slides on which thousands of purified proteins are printed at high density so that their activities can be tested in bulk.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup> He is a full professor of pharmacology and molecular sciences and oncology, and a member of the university's High Throughput Biology Center.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup><sup> • </sup><sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup> His laboratory uses these arrays to characterize the activities of large collections of proteins, to build signaling networks, and to identify biomarkers in human diseases and cancers.<sup>[3](https://www.hopkinsmedicine.org/research/labs/z/zhu-lab)</sup>

| Fact | Detail |
|---|---|
| Field | Molecular biology; proteomics technology and signaling networks |
| Position | Full professor of pharmacology and molecular sciences and oncology, Johns Hopkins School of Medicine<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup> |
| Training | B.S. chemistry, Peking University (1990); Ph.D., Clemson University (1999); Damon Runyon postdoctoral fellow with Mike Snyder, Yale University<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup><sup> • </sup><sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup> |
| Signature work | "Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling," *Cell*, 2009<sup>[4](https://www.cell.com/cell/fulltext/S0092-8674(09)01111-8)</sup> |
| Core technology | Protein purification at more than 4,000 proteins per day; microarrays carrying more than 15,000 proteins per slide<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup> |
| Industry role | Cofounder of CDI Laboratories, Inc., which commercializes the HuProt human protein microarray<sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup><sup> • </sup><sup>[5](https://www.cdilabs.com/)</sup> |

## Education and career

Zhu received his undergraduate degree in chemistry from [Peking University](https://www.edgepedia.org/peking-university) in Beijing in 1990 and earned his Ph.D. from [Clemson University](https://www.edgepedia.org/clemson-university) in 1999.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup> According to a [Chinese Academy of Sciences](https://www.edgepedia.org/chinese-academy-of-sciences) news item, he then held a Damon Runyon Postdoctoral Fellowship in Mike Snyder's laboratory at Yale University, where he worked on genetics and proteomics projects and was an inventor of functional protein microarrays; his postdoctoral training at Yale ended in 2004.<sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup><sup> • </sup><sup>[6](https://profiles.hopkinsmedicine.org/provider/heng-zhu/2777872)</sup> He joined the Johns Hopkins faculty in 2004.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup>

At [Johns Hopkins](https://www.edgepedia.org/johns-hopkins) he holds an appointment in the Department of Pharmacology and Molecular Sciences and is a member of the High Throughput Biology Center, with an affiliate faculty position at the Hopkins Oncology Center.<sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup> He was an associate professor as of July 2013 and is now a full professor of pharmacology and molecular sciences and oncology.<sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup><sup> • </sup><sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup>

## Protein microarray technology

According to a review in PMC, a functional protein microarray places many purified proteins at fixed positions on a glass slide, so that one assay can test thousands of proteins at once against a labeled probe. Zhu's 2001 *Science* paper, written during his Yale postdoctoral work, cloned 5,800 yeast open reading frames, overexpressed and purified the corresponding proteins, and printed them onto slides at high spatial density to form a yeast proteome microarray; probing it identified many new calmodulin- and phospholipid-interacting proteins.<sup>[7](https://doi.org/10.1126/science.1062191)</sup> 

His Johns Hopkins lab developed the two technologies that made proteome-scale arrays practical: high-throughput protein purification, exceeding 4,000 proteins per day, and high-density printing, exceeding 15,000 proteins per slide.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup> A paper describing the *E. coli* chip reported a purification protocol that yielded all 4,256 proteins encoded by the *E. coli* K12 strain within 10 hours.<sup>[8](https://preview-www.nature.com/articles/nmeth1148)</sup> The lab has fabricated proteome chips for budding yeast, herpesviruses, and *E. coli* K12.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup>

Protein chips of this kind are versatile probes: published assays cover protein-protein, protein-nucleic acid, protein-lipid, enzyme-substrate, and protein-drug interactions.<sup>[9](https://bcmb.bs.jhmi.edu/people/heng-zhu/)</sup> Reviews of the technology describe its use for binding to DNA, RNA, small molecules, and glycans, and for profiling post-translational modifications such as phosphorylation, ubiquitylation, acetylation, and nitrosylation.<sup>[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC3044218/)</sup> Using a human protein microarray, Zhu's team identified protein substrates of over 340 human kinases.<sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup> A later application screened 289 individual kinases against 4,191 full-length human proteins, building a network that connects 230 kinases to 2,591 specific in vivo phosphorylation sites on 652 proteins.<sup>[11](https://www.genomeweb.com/proteomics/hopkins-led-team-builds-high-res-activity-based-network-kinase-substrate-interac)</sup>

After joining Johns Hopkins, Zhu's group set out to extend the approach to the human proteome.

## Representative work

The 2009 *Cell* paper "Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling" applied a protein microarray strategy to DNA binding on a proteome scale. It identified 17,718 protein-DNA interactions between 460 DNA motifs predicted to regulate transcription and 4,191 human proteins of various functional classes. More than three hundred of the bound proteins were unconventional DNA-binding proteins, including RNA-binding proteins, mitochondrial proteins, and protein kinases.<sup>[4](https://www.cell.com/cell/fulltext/S0092-8674(09)01111-8)</sup>

The paper's most striking finding concerned ERK2, a protein kinase and one of these unconventional DNA-binding proteins. Characterization of its DNA binding in vitro and in vivo showed that ERK2 acts as a transcriptional repressor regulating interferon gamma signaling in mammalian cells.<sup>[4](https://www.cell.com/cell/fulltext/S0092-8674(09)01111-8)</sup>

A second 2009 *Cell* paper, "Protein Acetylation Microarray Reveals that NuA4 Controls Key Metabolic Target Regulating Gluconeogenesis," used an acetylation-focused array to show that NuA4 controls a key metabolic target regulating gluconeogenesis.<sup>[13](https://scholar.google.com/citations?hl=en&user=PLQVWdcAAAAJ)</sup>

## Current research

Zhu's current work centers on the impacts of DNA epigenetic modifications on transcriptional regulation, the characterization of functional GWAS SNPs, and biomarker discovery.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup> Recent chip applications in his lab include RNA-protein, live cell-protein, and lectin-protein interaction assays, protein ubiquitination and acetylation assays, human serum profiling, and biomarker identification in human inflammatory bowel diseases.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup> His lab also develops a highly multiplexed DAPPL platform alongside proteome arrays and VirD arrays.<sup>[1](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)</sup>

## Roles outside academia

Zhu is one of the cofounders of CDI Laboratories, Inc., a firm launched to commercialize the protein microarray technology; as of July 2013 he held two patents with seven pending, and he has planned to offer kinase research services based on his lab's work through the company.<sup>[2](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)</sup><sup> • </sup><sup>[11](https://www.genomeweb.com/proteomics/hopkins-led-team-builds-high-res-activity-based-network-kinase-substrate-interac)</sup> CDI Labs produces the HuProt human protein microarray, created by its cofounders, faculty members of the High Throughput Biology Center at Johns Hopkins, with support from the NIH Common Fund.<sup>[5](https://www.cdilabs.com/)</sup>
## References


1. [Heng Zhu, PhD - Johns Hopkins School of Medicine Faculty](https://www.hopkinsmedicine.org/profiles/details/heng-zhu)
2. [Dr. Heng Zhu from The Johns Hopkins University Visits TIPC, Chinese Academy of Sciences (2013)](http://english.ipc.cas.cn/news/icn/201307/t20130704_105541.html)
3. [Zhu Lab, Johns Hopkins Medicine](https://www.hopkinsmedicine.org/research/labs/z/zhu-lab)
4. https://www.cell.com/cell/fulltext/S0092-8674(09)01111-8
5. [CDI Labs](https://www.cdilabs.com/)
6. [Heng Zhu, PhD - Johns Hopkins Medicine provider profile](https://profiles.hopkinsmedicine.org/provider/heng-zhu/2777872)
7. [Global Analysis of Protein Activities Using Proteome Chips, Science (2001)](https://doi.org/10.1126/science.1062191)
8. [A proteome chip approach reveals new DNA damage recognition activities in Escherichia coli, Nature Methods](https://preview-www.nature.com/articles/nmeth1148)
9. [Heng Zhu - Hopkins BCMB](https://bcmb.bs.jhmi.edu/people/heng-zhu/)
10. [Functional protein microarray technology (review)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3044218/)
11. [Hopkins-led Team Builds High-res Activity-based Network of Kinase-substrate Interactions, GenomeWeb](https://www.genomeweb.com/proteomics/hopkins-led-team-builds-high-res-activity-based-network-kinase-substrate-interac)
12. [From 108 Kinases to the Human Proteome: A 25-Year Journey Toward Proteome-Scale Biology, CDI Labs Blog](https://www.cdilabs.com/blogs/25-year-journey-to-proteome-scale-biology)
13. [Heng Zhu - Google Scholar](https://scholar.google.com/citations?hl=en&user=PLQVWdcAAAAJ)
14. [MAPPING DNA BINDING - US Patent Application US20250101492A1](https://www.patents-review.com/a/20250101492-mapping-dna-binding.html)



---
*Topic: Encyclopedia › Life and health › Life and health scientists › Life scientists › Researchers in structural biology, biochemistry, and biophysics*

*Initially written Sep 21, 2026 · Reviewed: Sep 25, 2026; Sep 30, 2026 · Edited: Sep 25, 2026; Sep 30, 2026 · Last review: Sep 30, 2026*

*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*

License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license
